Showing results (2221-2230 of 2,232) with videos related to
Sort By:
Pageof 224
Journal for Immunotherapy of Cancer|October 25, 2024
Comparison of zuberitamab plus CHOP versus rituximab plus CHOP for the treatment of drug-naïve patients diagnosed with CD20-positive diffuse large B-cell lymphoma: a phase 3 trialZhiming Li, Wenqi Jiang, Hui Zhou, et al.Nature Communications|January 9, 2014
Two new susceptibility loci 1q24.2 and 11p11.2 confer risk to severe acneLi He, Wen-Juan Wu, Jian-Kang Yang, et al.Vox Sanguinis|March 18, 2026
Pre-donation deferral rates and causes among whole blood and apheresis platelet donors in China: A multi-centre retrospective study (2016-2024)Yuan Zhang, Shaojun Wei, Xinfeng Li, et al.Cancer Cell|March 19, 2020
Genomic and Transcriptomic Characterization of Natural Killer T Cell LymphomaJie Xiong, Bo-Wen Cui, Nan Wang, et al.Innovation (Cambridge (Mass.))|May 14, 2023
Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III studyHuijuan Zhong, Shu Cheng, Xi Zhang, et al.Haematologica|April 10, 2025
Dynamic change in Epstein-Barr virus DNA predicts prognosis in early stage natural killer/T-cell lymphoma with pegaspargase-based treatment: long-term follow-up and biomarker analysis from the NHL-004 multicenter randomized studyHuijuan Zhong, Shu Cheng, Jie Xiong, et al.Military Medical Research|April 8, 2025
Endovascular treatment for cerebral venous thrombosis: a multicenter study in ChinaHe-Tao Bian, Xia Wang, Gui-You Liu, et al.Infectious Diseases of Poverty|March 19, 2021
Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safetyJing-Tao Gao, Juan Du, Gui-Hui Wu, et al.Nature Communications|May 13, 2025
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsJulie A I Thoms, Feng Yan, Henry R Hampton, et al.Journal of Clinical Microbiology|October 26, 2023
A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERCSybren de Hoog, Thomas J Walsh, Sarah A Ahmed, et al.Pageof 224